Patient Capital Management is a Baltimore asset manager founded in 2020 by Samantha McLemore, CFA — Bill Miller's long-time co-manager (working together since 2002, running the flagship Opportunity Equity strategy since 2014). Continuing the Miller-school contrarian tradition, it practices "time arbitrage": exploiting behavioral mispricing to concentrate in controversial growth names (tech, healthcare, Bitcoin-related) at deep discounts to intrinsic value. Its site preserves Bill Miller's complete 1995-2022 market letters, alongside ongoing quarterly letters and webinars.
This is an introduction from Christina Malbon of Patient Capital on a podcast. Her main point: value investing shouldn't just mean buying cheap, mature companies. Instead, she splits it into three types—classic value, reasonably priced growth stocks, and early-stage startups. She also says cyclical stocks (companies tied to economic ups and downs) look especially attractive right now. But this is just a teaser—no data or specific companies are mentioned, so we'll have to wait for the full interview to see the evidence.
Christina Malbon represented Patient Capital on the "Engaging Alternatives Spotlight" podcast, sharing her value investing outlook. As a next-generation value investor, the firm classifies value into three categories: Classic Value, Attractively Priced Compounders, and Early-Stage Companies. The fir
Christina Malbon, representing Patient Capital, joined the "Engaging Alternatives Spotlight" podcast to introduce the firm's alternative value investing framework. She calls herself a "next-generation value investor," breaking value down into three categories — Classic Value, Attractively Priced Compounders, and Early-Stage Companies — and explicitly states that cyclical stocks are particularly attractive at present. The weightiest judgment in this chapter: value investing should not be sought only among traditional cheap stocks; rather, value should be redefined at different stages of the enterprise lifecycle and along different quality dimensions (Christina Malbon). It should be noted that this is a self-promotional introduction to the podcast; the supporting arguments may only be developed in the subsequent interview.
Christina Malbon believes that value investing should not be confined to traditional cheap stocks, but should instead be divided into three categories: Classic Value, Attractively Priced Compounders, and Early-Stage Companies. This is the core judgment of this chapter. The rationale is that different companies sit at different stages of the lifecycle, so value takes different forms — classic value corresponds to mature, undervalued assets; compounders correspond to a balance of quality and price; and early-stage companies correspond to high growth potential and high uncertainty. This framework also explains why the firm calls itself a "next-generation value investor."
At the sector level, she explicitly states that cyclical stocks are "particularly attractive," but this introductory passage does not elaborate on the rationale — whether it is undervaluation, a cyclical recovery, or earnings elasticity is not specified in the original text. The emphasis on team diversity echoes this framework: a diversified team brings multi-dimensional perspectives, and a diversified portfolio avoids betting on a single value type. This chapter is merely the podcast introduction and provides no specific data or individual stock cases, so these views remain to be tested in the subsequent interview.
| Target | Guest's Stance | Key Data |
|---|---|---|
| (No specific targets mentioned in this chapter) | — | — |
1. Value investing should be re-divided into three categories — classic value, low-priced compounders, and early-stage companies — rather than traditional deep value alone. — Christina Malbon
2. Cyclical stocks are particularly attractive at present. — Christina Malbon, speaking on behalf of Patient Capital